Announcements Trials
Browse Landscape

Phase

Phase 1 35Phase 2 12Phase 1/2 5Phase 4 3Phase 3 3Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15Thoracic 8Genitourinary 7Gastrointestinal 5Head & Neck 3Gynecologic 2Tumor-Agnostic 1

Conditions

Adenocarcinoma 1

Interventions

Blood Specimen Collection 25Standard of Care 23Surveys and Questionnaires 18Methods 14Exercise 14Educational Status 14Interviews as Topic 13Magnetic Resonance Spectroscopy 12Biopsy 12Radiosurgery 11Palliative Care 10Radiotherapy 9Practice Guidelines as Topic 9Early Intervention, Educational 9Music Therapy 8Therapeutics 7Control Groups 7Positron Emission Tomography Computed Tomography 6Patient Navigation 5Mindfulness 5Fluorodeoxyglucose F18 5Telemedicine 4Geriatric Assessment 4Decision Support Techniques 4Counseling 4Behavior Therapy 4Art Therapy 4Yoga 3Sunitinib 3Quality of Life 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Docetaxel × Tumor-Agnostic × Clear all
NCT01295086 2020-11-02

Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

Odense University Hospital

Phase NA Completed
27 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡